Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

bioAffinity Technologies (BIAF) Accounts Payables: 2022-2025

Historic Accounts Payables for bioAffinity Technologies (BIAF) over the last 3 years, with Sep 2025 value amounting to $940,761.

  • bioAffinity Technologies' Accounts Payables rose 20.16% to $940,761 in Q3 2025 from the same period last year, while for Sep 2025 it was $940,761, marking a year-over-year increase of 20.16%. This contributed to the annual value of $987,311 for FY2024, which is 63.25% up from last year.
  • bioAffinity Technologies' Accounts Payables amounted to $940,761 in Q3 2025, which was down 19.58% from $1.2 million recorded in Q2 2025.
  • Over the past 5 years, bioAffinity Technologies' Accounts Payables peaked at $1.4 million during Q1 2025, and registered a low of $146,537 during Q1 2023.
  • Its 3-year average for Accounts Payables is $749,787, with a median of $827,407 in 2023.
  • Per our database at Business Quant, bioAffinity Technologies' Accounts Payables soared by 452.09% in 2023 and then declined by 5.37% in 2024.
  • bioAffinity Technologies' Accounts Payables (Quarterly) stood at $345,042 in 2022, then surged by 75.28% to $604,789 in 2023, then surged by 63.25% to $987,311 in 2024, then climbed by 20.16% to $940,761 in 2025.
  • Its Accounts Payables stands at $940,761 for Q3 2025, versus $1.2 million for Q2 2025 and $1.4 million for Q1 2025.